Search results for "Multicenter"

showing 10 items of 378 documents

Anti-transglutaminase autoantibodies in saliva. Usefulness of the radioimmunological test in coeliac children and adolescents: A multicenter study

2013

SalivaPathologymedicine.medical_specialtyHepatologybiologyTissue transglutaminasebusiness.industryGastroenterologyAutoantibodyMulticenter studyImmunologybiology.proteinmedicinebusinessDigestive and Liver Disease
researchProduct

Accuracy of cotinine serum test to detect the smoking habit and its association with periodontal disease in a multicenter study

2016

Background The validity of the surveys on self-reported smoking status is often questioned because smokers underestimate cigarette use and deny the habit. It has been suggested that self-report should be accompanied by cotinine test. This report evaluates the usefulness of serum cotinine test to assess the association between smoking and periodontal status in a study with a large sample population to be used in studies with other serum markers in epidemiologic and periodontal medicine researches. Material and Methods 578 patients who were part of a multicenter study on blood biomarkers were evaluated about smoking and its relation to periodontal disease. Severity of periodontal disease was …

SerumMalemedicine.medical_specialtyPopulationDentistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeriodontal diseaseInternal medicineMedicineHumansClinical significance030212 general & internal medicinePeriodontitiseducationCotinineGeneral DentistryPeriodontal DiseasesPeriodontitiseducation.field_of_studyBiological markersOral Medicine and Pathologybusiness.industryResearchSmokingReproducibility of Results030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseTest (assessment)OtorhinolaryngologyClinical attachment lossMulticenter studychemistryUNESCO::CIENCIAS MÉDICASSurgeryFemaleSelf ReportbusinessCotinineBiomarkersMedicina oral, patologia oral y cirugia bucal
researchProduct

PROGNOSTIC VALUE OF ESTIMATED GLOMERULAR FILTRATION RATE IN HOSPITALIZED ELDERLY PATIENTS

2013

A multicenter observational study, REPOSI (REgustri POliterapie Società Italiana di Medicina Interna), was conducted to assess the prognostic value of glomerular filtration rate (eGFR) on in-hospital mortality, hospital readmission and death within 3 months, in a sample of elderly patients (n=1,363) admitted to 66 internal medicine and geriatric wards. Bases on eGFR, calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, subjects at hostpital admission were classified into three groups: group 1 with normal eGFR (60 ml/min/1.73m2, reference group), group 2 with moderately reduced eGFR (30-59 ml/min/1.73 m2) and group 3 with severely reduced eGFR (<30 ml/m…

Settore MED/09 - Medicina InternaMulticenter study in-hospital elderly patients comorbidity polypharmacy eGFR
researchProduct

Improvement of quality of life during treatment with anabolic therapy: results of multicenter study

2012

Settore MED/34 - Medicina Fisica E Riabilitativaanabolic therapy multicenter study parathyroid hormone
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures

2009

A variety of powerful test procedures are available for the analysis of clinical trials addressing multiple objectives, such as comparing several treatments with a control, assessing the benefit of a new drug for more than one endpoint, etc. However, some of these procedures have reached a level of complexity that makes it difficult to communicate the underlying test strategies to clinical teams. Graphical approaches have been proposed instead that facilitate the derivation and communication of Bonferroni-based closed test procedures. In this paper we give a coherent description of the methodology and illustrate it with a real clinical trial example. We further discuss suitable power measur…

Statistics and ProbabilityTest strategyEndpoint DeterminationEpidemiologyComputer scienceControl (management)Analysis of clinical trialsMachine learningcomputer.software_genresymbols.namesakeDrug TherapyComputer GraphicsConfidence IntervalsHumansMulticenter Studies as TopicRandomized Controlled Trials as Topicbusiness.industryVariety (cybernetics)Test (assessment)Clinical trialBonferroni correctionClinical Trials Phase III as TopicData Interpretation StatisticalMultiple comparisons problemsymbolsArtificial intelligencebusinessAlgorithmcomputerStatistics in Medicine
researchProduct

A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials

2021

In heart failure trials efficacy is usually proven by a composite endpoint including cardiovascular death (CVD) and recurrent heart failure hospitalisations (HFH), evaluated with time-to-first-event analysis based on a Cox model. As a considerable fraction of events is ignored that way, recurrent event[for full text, please go to the a.m. URL]

Statistics and Probabilitymedicine.medical_specialtyEpidemiology610 Medizinheart failureleast false parameterPositive correlationjoint frailty modelCorrelationLWYY model610 Medical sciencesInternal medicineMulticenter trialmedicineHumansTreatment effectFraction (mathematics)proportional rates modelsProportional Hazards ModelsProportional hazards modelbusiness.industry610 Medical sciences; Medicinemedicine.diseasecomposite endpointRecurrent eventTreatment Outcomeddc: 610recurrent eventsHeart failureCardiologybusiness
researchProduct

Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER)

2018

Background Percutaneous coronary intervention in complex bifurcation lesions is prone to suboptimal implantation results and is associated with increased risk of subsequent clinical events. Angiographic ambiguity is high during bifurcation stenting, but it is unknown if procedural guidance by intravascular optical coherence tomography (OCT) improves clinical outcome. Methods and design OCTOBER is a randomized, investigator-initiated, multicenter trial aimed to show superiority of OCT-guided stent implantation compared to standard angiographic-guided implantation in bifurcation lesions. The primary outcome measure is a 2-year composite end point of cardiac death, target lesion myocardial inf…

Target lesionMalemedicine.medical_specialtyBiolääketieteet - Biomedicinemedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyLesion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionMulticenter trialmedicineHumans030212 general & internal medicineMyocardial infarctionTomographyAgedUnstable anginabusiness.industrySisätaudit - Internal medicineCoronary StenosisPercutaneous coronary interventionStentDrug-Eluting StentsMiddle Agedmedicine.diseaseCoronary VesselsStenosisTreatment OutcomeOptical CoherenceSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleRadiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessTomography Optical CoherenceAmerican Heart Journal
researchProduct

Therapy response evaluation of malignant lymphoma in a multicenter study: comparison of manual and semiautomatic measurements in CT.

2014

Purpose: Comparison of manual one-/bi-dimensional measurements versus semi-automatically derived one-/bi-dimensional and volumetric measurements for therapy response evaluation of malignant lymphoma during CT follow-up examinations in a multicenter setting. Materials and Methods: MSCT data sets of patients with malignant lymphoma were evaluated before (baseline) and after two cycles of chemotherapy (follow-up) at radiological centers of five university hospitals. The long axis diameter (LAD), the short axis diameter (SAD) and the bi-dimensional WHO of 307 target lymph nodes were measured manually and semi-automatically using dedicated software. Lymph node volumetry was performed semi-automa…

ThoraxAdultMalemedicine.medical_specialtyRadiation DosageMalignant lymphomaYoung AdultAntineoplastic Combined Chemotherapy ProtocolsImage Interpretation Computer-AssistedMultidetector Computed TomographyMedicineHumansRadiology Nuclear Medicine and imagingLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryLymphoma Non-HodgkinMediastinumRetrospective cohort studyMiddle Agedmedicine.diseaseHodgkin DiseaseLymphomamedicine.anatomical_structureTherapy responseTreatment OutcomeMulticenter studyFemaleRadiologybusinessRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct